Inclusion Criteria:  Age≥18 years, < 80 years, regardless of sex; Patients with clinically definite diagnosis of acute ischemic stroke and undergo intravenous thrombolysis; Baseline NIHSS >= 5, and <= 25; Baseline GCS ≥8; Signed and dated informed consent is obtained  Exclusion Criteria:  Patients who undergo endovascular treatment; mRS ≥ 2 before the onset of the disease; Double upper limbs or lower limbs paralysis was found in this case; Active bleeding of organs within 6 months of admission or current, including cerebral hemorrhage, subarachnoid hemorrhage, gastrointestinal hemorrhage, fundus hemorrhage and so on; Other intracranial lesions, such as cerebrovascular malformation cerebral venous diseases, tumor and other diseases involving the brain; Concurrent use of anticoagulation drugs including Warfarin, dabigatran, rivaroxaban; Severe organ dysfunction or failure; Patients suffering from severe hematological diseases or severe coagulation disorder dysfunction Those who have a history of severe trauma or had major surgery within 6 months prior to admission; Those who have a history of atrial fibrillation; The patients who have the contraindication of remote ischemic conditioning treatment, such as severe soft tissue injury, fracture or vascular injury in the upper limb#Acute or subacute venous thrombosis, arterial occlusive disease, subclavian steal syndrome, etc; Pregnant or lactating women; Previous remote ischemic conditioning therapy or similar treatment; Patients with a life expectancy of less than 3 months or patients unable to complete the study for other reasons; Severe hepatic and renal dysfunction; Unwilling to be followed up or treated for poor compliance; He/She is participating in other clinical research or has participated in other clinical research or has participated in this study within 3 months prior to admission; Other conditions that the researchers think are not suitable for the group.